These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 8917641

  • 1. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design.
    Schulze-Gahmen U, De Bondt HL, Kim SH.
    J Med Chem; 1996 Nov 08; 39(23):4540-6. PubMed ID: 8917641
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, Kontopidis G, Meades C, Mezna M, Thomas M, Wood G, Lane DP, Fischer PM.
    Chem Biol; 2004 Apr 08; 11(4):525-34. PubMed ID: 15123247
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, Le HV, Guzi TJ, Dwyer MP, Paruch K, Doll RJ, Lees E, Parry D, Seghezzi W, Madison V.
    Biopolymers; 2008 May 08; 89(5):372-9. PubMed ID: 17937404
    [Abstract] [Full Text] [Related]

  • 9. Molecular determinants for ATP-binding in proteins: a data mining and quantum chemical analysis.
    Mao L, Wang Y, Liu Y, Hu X.
    J Mol Biol; 2004 Feb 20; 336(3):787-807. PubMed ID: 15095988
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
    Jaramillo C, de Diego JE, Hamdouchi C, Collins E, Keyser H, Sánchez-Martínez C, del Prado M, Norman B, Brooks HB, Watkins SA, Spencer CD, Dempsey JA, Anderson BD, Campbell RM, Leggett T, Patel B, Schultz RM, Espinosa J, Vieth M, Zhang F, Timm DE.
    Bioorg Med Chem Lett; 2004 Dec 20; 14(24):6095-9. PubMed ID: 15546737
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
    Kim MK, Min J, Choi BY, Lim H, Cho YH, Lee CH.
    J Microbiol Biotechnol; 2007 Oct 20; 17(10):1712-6. PubMed ID: 18156791
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
    De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH.
    Eur J Biochem; 1997 Jan 15; 243(1-2):518-26. PubMed ID: 9030780
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M, Gortat A, Mondragón L, Bachs O, Pérez-Payá E.
    ChemMedChem; 2009 Jan 15; 4(1):19-24. PubMed ID: 19039815
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.